Eli Lilly has cut off access to 340B discount pricing for some hospital pharmacies that did not hand over de-identified in-house claims data by the company’s June 8 deadline, escalating a long-simmering fight over who polices the federal discount program and how. Lilly says it is trying to stop duplicate discounts. Hospital trade groups say the move is unlawful and will squeeze already thin safety-net care.
What Lilly Says It Did
In a June 1 letter to the Health Resources and Services Administration (HRSA), Lilly told regulators it had received in-house claims submissions from roughly 70% of the estimated 2,350 covered entities that buy Lilly medicines at 340B prices, totaling nearly 800,000 claims since Jan. 1. For the remaining holdouts, the Indianapolis-based drugmaker said it warned an initial group that wholesalers would be told to suspend 340B pricing if the requested data did not arrive in time, with similar enforcement to follow in the “weeks ahead,” according to a copy of Lilly’s letter published by Stat.
Hospital Groups Push Back
Hospital leaders see the move less as a data integrity push and more as a unilateral rewrite of federal policy. The American Hospital Association called Lilly’s decision an “extraordinary” step and urged Congress and the Department of Health and Human Services to intervene, warning that manufacturer-imposed demands would drain scarce hospital resources and threaten patient access. In a statement, American Hospital Association President Rick Pollack said regulators, not drugmakers, should be the ones to decide how the 340B program is administered.
Why Indiana Is Watching
The clash is playing out under a bright spotlight in Indiana, where Lilly is headquartered and where state officials are already rethinking how 340B interacts with Medicaid. Earlier this year, the Indiana Family and Social Services Administration floated a rule to end Medicaid reimbursement that is tied to 340B purchases, an approach the agency said could save the state money. It later carved out an exemption for federally qualified health centers, as reported by the Indiana Capital Chronicle in its initial and follow-up coverage. Local hospital executives argue that stripping away or narrowing 340B benefits could put rural services and specialized care on the chopping block.
Legal and Regulatory Stakes
In its June letter, Lilly cites two federal courts of appeals and longstanding HRSA guidance as support for its position that manufacturers can request standard information as a condition of offering 340B prices. The company casts its claims-data demand as an integrity measure meant to spot duplicate discounts and stay compliant with obligations under the Inflation Reduction Act, again pointing to its correspondence made public by Stat.
The 340B program itself is administered by HRSA, which also runs an Administrative Dispute Resolution process for billing and overcharge fights. That pathway allows disagreements between manufacturers and covered entities to be funneled into an agency-run adjudication process if needed, according to HRSA.
What Hospitals and Patients May Face
Hospital groups warn that losing manufacturer discounts will quickly show up on balance sheets. Higher acquisition costs for critical drugs, they say, could force systems to pull money from clinical services to keep pharmacy budgets afloat. Industry coverage tracking the fallout reports that hospitals which lose 340B eligibility for specific brands or sites could face immediate financial strain and may push higher charges onto insurers or patients while the dispute drags on, according to Becker’s Hospital Review.
Lilly, for its part, says it is still willing to talk with covered entities that agree to share the requested de-identified claims data. Hospital trade groups and state officials, meanwhile, are pressing federal regulators for a clear, authoritative ruling on how far drugmakers can go. Observers note that whatever HRSA or Congress decides could set a precedent for other manufacturers that have rolled out similar claims-data policies in recent months and could trigger further federal oversight or legislative interest, according to reporting by Fierce Healthcare.
